Evidence-Based Complementary and Alternative Medicine

Research Article

Resveratrol Downregulates Interleukin-6-Stimulated Sonic Hedgehog Signaling in Human Acute Myeloid Leukemia

Table 2

Characteristics of AML patients (M3 excluded) collected in this study.


Patient number	BM or PB collection	Alive or died	New diagnose or relapse	Type	Gender	Age (yr)	Average values^a

1	BM	Alive	New diagnose	M1	F	58	Age: 46.8 ± 6.5 yr old
2	BM	Alive	New diagnose	M2	M	30
3	BM	Alive	New diagnose	M0	M	53
4	BM	Alive	New diagnose	M2	M	36
5	BM	Alive	New diagnose	M2	F	34
6	BM	Alive	New diagnose	M1	M	70

7	PB	Alive	New diagnose	M2	M	30	Age: 55.5 ± 7.6 yr old IL-6: 10.1 ± 6.3 pg/mL N-Shh: 1.7 ± 0.2 fold
8	PB	Alive	New diagnose	M1	M	52
9	PB	Alive	New diagnose	M4	F	84
10	PB	Alive	New diagnose	M1	M	75
11	PB	Alive	New diagnose	M2	M	88
12	PB	Alive	New diagnose	M1	F	60
13	PB	Alive	New diagnose	M2	M	84
14	PB	Alive	New diagnose	M2	M	59
15	PB	Alive	Relapse	M1	F	29
16	PB	Alive	Relapse	M2	M	21
17	PB	Alive	Relapse	M2	M	29

18	PB	Died	New diagnose	M2	M	51	Age: 69.6 ± 2.8 yr old IL-6: 116.6 ± 54.9 pg/mL* N-Shh: 2.4 ± 0.2 fold*
19	PB	Died	New diagnose	M1	M	80
20	PB	Died	New diagnose	M0	M	71
21	PB	Died	New diagnose	M1	F	69
22	PB	Died	New diagnose	M2	M	78
23	PB	Died	New diagnose	M2	F	75
24	PB	Died	Relapse	M4	M	66
25	PB	Died	Relapse	M2	F	68
26	PB	Died	Relapse	M1	F	68

The average age and IL-6 value of normal control were 45.5 ± 8.5 yr old and 0.8 ± 0.1 pg/mL, respectively. The relative fold of N-Shh in AML was normalized to the normal control, and the data were expressed as mean ± SE.
* P < 0.05 as compared to the living AML patients. The results were calculated from at least three independent experiments and expressed as mean ± standard error (SE).